+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Lymphokine-activated killer (LAK) cell activity in tumor-infiltrating lymphocytes from non-small cell lung cancer



Lymphokine-activated killer (LAK) cell activity in tumor-infiltrating lymphocytes from non-small cell lung cancer



American Journal of Clinical Pathology 92(4): 435-446



Tumor-infiltrating lymphocytes (TILs) are often seen in non-small cell lung cancers (NSCCs). Their functional role in the pathogenesis of lung cancer is unknown. The authors studied TILs in 27 patients with NSCC and determined the following: (1) the immunologic phenotype as defined by monoclonal antibodies against various surface markers, (2) activation state as indicated by interleukin-2 (IL-2) receptor expression and the kinetics of proliferation response to IL-2, and (3) the ability to develop lymphokine-activated killer (LAK) type cytotoxicity against both natural killer (NK)-resistant tumor cell targets (M14) and fresh autologous tumor cells. The authors' results show TILs from NSCCs to be a heterogeneous population composed of T-cells, B-cells, monocytes, and NK cells in frequencies similar to those found in peripheral blood lymphocytes (PBLs). TILs demonstrated increased IL-2 receptor expression and a more rapid proliferative response to IL-2 than PBLs, implying activation of TILs by the tumor milieu. Finally, TILs generated cytotoxicity against NK-sensitive (K562) and NK-resistant (M14) cell line targets consistently after in vitro treatment with IL-2 but were less consistent in their ability to lyse fresh autologous tumor cells and less effective than PBL LAK cells in lysing all targets. Comparison with LAK cells generated from normal volunteers suggests that decreased killing of autologous tumor cells only partially results from an inherent resistance to lysis by fresh NSCC targets. It appears, therefore, that tumor cells taken from NSCCs are not readily killed by the immune cells that infiltrate the tumor stroma and that this failure does not result from nonspecific immune deficiency in TILs.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 040614850

Download citation: RISBibTeXText

PMID: 2552792

DOI: 10.1093/ajcp/92.4.435


Related references

Lymphokine-activated killer cell activity of peripheral blood, spleen, regional lymph node, and tumor infiltrating lymphocytes in gastric cancer patients. Journal Of Surgical Oncology. 55(3): 179-185, 1994

Suppression of lymphokine-activated killer cell generation by tumor-infiltrating lymphocytes. Clinical Immunology and Immunopathology 59(3): 407-416, 1991

Antitumor and proliferative responses of il 2 expanded tumor infiltrating lymphocytes til vs lymphokine activated killer lak cells derived from patients with advanced renal cell cancer rcc. Federation Proceedings: 1508, 1987

Lymphokine-activated killer cell activity of tumour-infiltrating lymphocytes from gastric carcinoma. Medical Science Research 22(8): 567-569, 1994

Effects of systemic recombinant interleukin-2 on natural killer and lymphokine activated killer activity of human tumor infiltrating lymphocytes. Cancer Research 48(5): 1180-1183, 1988

Influence of IFN-gamma on human renal cell carcinomas and their altered recognition by tumor-infiltrating lymphocytes and lymphokine-activated killer cells. Immunobiology 191(2-3): 214, 1994

Lymphokine-activated killer cell induction in tumor-infiltrating leukocytes from colon cancer patients. Cancer 64(11): 2238-2242, 1989

Lymphokine activated killer cell generation in non small cell lung cancer. Chest 92(2 Suppl.): 87S, 1987

Lymphokine activated killer cell induction in tumor infiltrating leukocytes and peripheral blood mononuclear cells from colon cancer patients. Proceedings of the American Association for Cancer Research Annual Meeting 29: 406, 1988

A Tumor Cell-Selective Inhibitor of Mitogen-Activated Protein Kinase Phosphatases Sensitizes Breast Cancer Cells to Lymphokine-Activated Killer Cell Activity. Journal of Pharmacology and Experimental Therapeutics 361(1): 39-50, 2017

Lymphokine-activated killer cell susceptibility in epirubicin-resistant and parental human non-small cell lung cancer (NSCLC). Biologia 62(2): 232-237, 2007

Generation and activation of tumor-infiltrating lymphocytes (TIL) within the scope of lymphokine activated killer cell therapy (LAK-TIL therapy) in patients with advanced breast and ovarian carcinoma. Gynakologisch-Geburtshilfliche Rundschau 35(Suppl. 1): 161-165, 1995

Analysis of HLA-class-I specific natural killer cell receptors expressed on T lymphocytes infiltrating non-small-cell lung cancer. Lung Cancer 34(3): 395-405, 2001

Lymphokine activated killer cell phenomenon 4. lysis by lymphokine activated killer cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors. Journal of the National Cancer Institute 75(1): 67-76, 1985

Lymphokine activated killer lak cell induction in tumor infiltrating leukocytes til and peripheral blood mononuclear cells pbmc from colon cancer patients. Proceedings of the American Association for Cancer Research Annual Meeting 28: 371, 1987